

1 **Long-term immune persistence induced by two-dose BBIBP-CorV**
2 **vaccine with different intervals, and immunogenicity and safety of a**
3 **homologous booster dose in high-risk occupational population**
4 **Secondary Study Based on a Randomized Clinical Trial**

5 Tian Yao*, Xiaohong Zhang*, Shengcai Mu*, Yana Guo, Xiuyang Xu, Junfeng Huo, Zhiyun
6 Wei, Ling Liu, Xiaoqing Li, Hong Li, Rongqin Xing, **Yongliang Feng[†], Jing Chen[†], Lizhong**
7 **Feng[†] & Suping Wang[†]**

8 *Contributed equally

9 †Joint supervisors

10 First Hospital/First Clinical Medical College of Shanxi Medical University, Taiyuan, China
11 (T Yao MD)

12 School of Public Health, Shanxi Medical University, Taiyuan, China (Prof S Wang MD, Y
13 Feng MD, Y Guo BM, X Xu BM)

14 Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University,
15 Taiyuan, China (Prof S Wang MD, Y Feng MD, T Yao MD, Y Guo BM, X Xu BM)

16 Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China (L Feng MM, J
17 Chen MM, X Zhang MM, S Mu MM, J Huo MM, Z Wei MM, L Liu MM, X Li MM, H Li
18 MM)

19 Shanxi Provincial Key Laboratory for major infectious disease response (L Feng MM, J Chen
20 MM, X Zhang MM, S Mu MM, J Huo MM, Z Wei MM, L Liu MM, X Li MM, H Li MM)

21 Outpatient Department of Shanxi Aviation Industry Group Co. LTD (R Xing BM)

22 Correspondence to:

23 Suping Wang, School of Public Health, Center of Clinical Epidemiology and Evidence Based
24 Medicine, Shanxi Medical University, Taiyuan, 030001, China

25 supingwang@sxmu.edu.cn

26 Lizhong Feng, Shanxi Provincial Center for Disease Control and Prevention, Shanxi
27 Provincial Key Laboratory for major infectious disease response, Taiyuan, 030012, China

28 1508717672@qq.com

29 Jing Chen, Shanxi Provincial Center for Disease Control and Prevention, Shanxi Provincial
30 Key Laboratory for major infectious disease response, Taiyuan, 030012, China

31 524210737@qq.com

32 Yongliang Feng, School of Public Health, Center of Clinical Epidemiology and Evidence
33 Based Medicine, Shanxi Medical University, Taiyuan, 030001, China

34 yongliang.feng@sxmu.edu.cn

35 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

36

37 **Abstract**

38 **Background**

39 BBIBP-CorV vaccine with two doses and an interval of 3-4 weeks had been proved to
40 have good immunogenicity and efficacy as well as an acceptable safety profile
41 according to our initial research and other similar studies. Maintaining adequate
42 neutralizing antibody levels is also necessary for long-term protection, especially in
43 the midst of the COVID-19 pandemic. Our aim was to evaluate the immune
44 persistence of neutralizing antibody elicited by BBIBP-CorV vaccines with day 0-14,
45 0-21 and 0-28 schedule, and assess the immunogenicity and safety of a homologous
46 booster dose in the high-risk occupational population aged 18-59 years.

47 **Methods**

48 A total of 809 eligible participants, aged 18-59 years, were recruited and randomly
49 allocated to receive BBIBP-CorV vaccine with day 0-14, 0-21 or 0-28 schedule
50 respectively between January and May 2021 in Taiyuan City, Shanxi Province, China
51 among the public security officers and the airport ground staff in initial study. In this
52 secondary study, the responders ($\text{GMT} \geq 16$) at day 28 after priming two-dose vaccine
53 were followed up at months 3, 6 and 10 to evaluate the immune persistence of three
54 two-dose schedules. At month 10, eligible participants of three two-dose schedules
55 were received a homologous booster dose respectively (hereafter abbreviated as
56 0-14d-10m group, 0-21d-10m group and 0-28d-10m group), and followed up at day
57 28 post-booster to assess the safety and immunogenicity of the booster dose. The
58 contents of follow-up included the blood samples, oropharyngeal/nasal swabs, and
59 adverse reactions collection. The main outcomes of the study included geometric
60 mean titers (GMT) of neutralizing antibody to live SARS-CoV-2, the positive rates of
61 different criteria and the constituent ratio of GMT of neutralizing antibodies at
62 different follow-up point. Meanwhile, we explored the kinetics of antibody levels of
63 different vaccination regimens by generalized estimating equations (GEE) and used
64 exponent curve model to predict the duration of maintaining protected antibody after
65 the booster dose. We also determined predictors of maintaining protected antibody
66 level within 10 months after the second dose by Cox proportional hazards regression
67 model and nomogram. The trial was registered with ChiCTR.org.cn
68 (ChiCTR2100041705, ChiCTR2100041706).

69 **Results**

70 The number of 241, 247 and 256 responders ($\text{GMT} \geq 16$) at day 28 after two-dose
71 BBIBP-CorV vaccine in 0-14d, 0-21d and 0-28d schedule were followed-up at
72 months 3, 6, and 10 for immune persistence evaluation. At month 10, a total of 390
73 participants were eligible and received a booster dose with 130 participants in the
74 0-14d-10m, 0-21d-10m and 0-28d-10m group respectively, of whom 74.1% (289/390)

75 were male, with a mean age of 37.1 ± 10.3 years. The GMT of neutralizing antibody in
76 0-28d-10m and 0-21d-10m group were significantly higher than 0-14d-10m group
77 at month 3 (GMT: 71.6 & 64.2 vs 46.4, $P < 0.0001$), month 6 (GMT: 47.1 & 42.8 vs
78 30.5, $P < 0.0001$) and month 10 (GMT: 32.4 vs 20.3, $P < 0.0001$; 28.8 vs 20.3,
79 $P=0.0004$) after the second dose. A sharply decrease by 4.85-fold (GMT: 94.4-20.3),
80 4.67-fold (GMT: 134.4-28.8) and 4.49-fold (GMT: 145.5-32.4) was observed from
81 day 28 to month 10 after the second dose in 0-14d-10m, 0-21d-10m and 0-28d-10m
82 group, respectively, and they had similar decline kinetics ($P=0.67$). At 28 days after
83 booster dose, a remarkable rebound in neutralizing antibody (GMT: 246.2, 277.5 and
84 288.6) were observed in three groups, respectively. Notably, the GMT after booster
85 dose was not affected by priming two-dose schedule. The predictive duration of
86 neutralizing antibody declining to the cutoff level of positive antibody response may
87 be 18.08 months, 18.83 months and 19.08 months after booster dose in three groups,
88 respectively. Long-term immune persistence within 10 months after the second dose
89 was associated with age<40, female, and history of influenza vaccination. All adverse
90 reactions were mild after the booster injection. None of the participants were infected
91 SARS-CoV-2 during the trial period.

92 **Conclusions**

93 The priming two-dose BBIBP-CorV vaccine with 0-28 days and 0-21 days schedule
94 could lead a longer persistence of neutralizing antibody than 0-14 days schedule.
95 Maintaining long-term immune persistence was also associated with age<40, female,
96 and history of influenza vaccination. Regardless of priming two-doses vaccination
97 regimens, a homologous booster dose led to a strong rebound in neutralizing antibody
98 and might elicit satisfactory persistent immunity.

99 **Keywords:** BBIBP-CorV; vaccination interval; Long-term immune persistence;
100 booster dose; immunogenicity; safety; high-risk occupational population

101 **Background**

102 Spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
103 has led to a substantial threat to public health worldwide. Globally, as of 20, June
104 2022, there have been 536.59 million confirmed cases of COVID-19, including 6.32
105 million deaths, according to the World Health Organization (WHO) COVID-19
106 Dashboard [1]. Vaccination is the most effective approach to the long-term strategy of
107 COVID-19 prevention and control. WHO listed the BBIBP-CorV vaccine for
108 emergency use on 7 May 2021, giving the approval for this vaccine to be rolled out
109 globally [2]. Our initial research and other similar studies indicated that a longer
110 interval (21 days and 28 days) between the first and second BBIBP-CorV vaccination
111 produced higher neutralizing antibody levels compared with a shorter interval
112 schedule (0-14 day) [3, 4].

113 Adequate neutralizing antibody levels could serve as a correlation of protection for
114 vaccines against SARS-CoV-2 in humans [5-7], but immune protection from infection
115 may wane with time as neutralizing antibody levels decline [6]. Whereas vaccines
116 induce durable T and B cell memory to SARS-CoV-2 [8, 9], strong evidence revealed
117 the crucial protective role for neutralizing serum antibodies[6] due to their ability to
118 block the viruses from entering the host cells directly [10]. So, maintaining adequate
119 neutralizing antibody levels is more necessary for long-term protection, especially
120 during the midst of the COVID-19 pandemic.

121 Recent studies indicated that binding or neutralizing SARS-CoV-2 antibodies
122 elicited by multiple types of vaccines (mRNA vaccines, adenovirus-vectored vaccines,
123 and inactivated vaccines et al) declined to varying degrees over time after priming
124 full-schedule vaccination, and showed substantial descent by 6 to 12 months [11-17].
125 Meanwhile, age, sex, comorbidities and immunosuppressed condition had an impact
126 on neutralizing antibody loss [17-19]. However, lasting immune response can
127 certainly be affected by spacing between the doses [20], and a complete picture of the
128 kinetics of long-term immune persistence elicited by priming two-dose BBIBP-CorV
129 vaccine with different vaccination interval is not yet available. Besides, the fading
130 immune response and the emergence of the Omicron (B.1.1.529) variant had raised
131 concerns about the booster dose. Recent research revealed that a booster dose of
132 different type of SARS-CoV-2 vaccine could induce remarkable high neutralizing
133 antibody levels [21-23]. Nevertheless, the safety and immunogenicity of a booster
134 dose with different priming two-dose BBIBP-CorV vaccination regimens are yet to be
135 thoroughly evaluated, especially in the high-risk occupational population.

136 Consequently, this paper assessed immune persistence of priming two-dose
137 BBIBP-CorV inactivated vaccines, and evaluated the immunogenicity and safety of a
138 homologous booster dose among three different vaccination regimens based on our

139 initial study. Meanwhile, we explored the kinetics of neutralizing antibody levels of
140 different vaccination regimens and determined predictors of maintaining protected
141 antibody levels, and constructed an exponent curve model to predict neutralizing
142 antibody decay after booster dose.

143 **Methods**

144 **Study design and participants**

145 Between on January, 2021 and May, 2021, a randomized, controlled phase IV clinical
146 trial of BBIBP-CorV vaccine with three two-dose schedules was conducted in
147 Taiyuan City, Shanxi Province, China. Public security officers and airport ground staff
148 aged 18-59 years, without previous SARS-CoV-2 vaccination and infection were
149 eligible for enrollment. A complete list of inclusion and exclusion criteria can be
150 found in a previous publication [3] (see protocol 2 p 1). After initial study, participants
151 who were neutralizing antibody positive [geometric mean titer (GMT) of 16, positive
152 response was defined as at least a 4-fold increase of neutralizing antibody titers over
153 baseline (4)] at day 28 after priming two-dose vaccine were followed-up extended to
154 November, 2021 (10 month after priming two-dose vaccination) for assessing the
155 immune persistence of three two-dose schedules of BBIBP-CorV vaccine.
156 Subsequently, on Nov 26, 2021, some participants who met the inclusion and
157 exclusion criteria were eligible to receive the booster injection for evaluating the
158 safety and immunogenicity of booster dose. Inclusion criteria included that (1) No an
159 unacceptable adverse event; (2) No SARS-CoV-2 infection during the follow-up
160 period; (3) Completed the initial two doses of vaccination; (4) be able and willing to
161 receive the booster dose injection. Exclusion criteria included that (1) A COVID-19
162 vaccine other than the experimental vaccine was used during the study period; (2)
163 Acute or new chronic disease occurs during follow-up; (3) other vaccination history
164 within 14 days before vaccination; (4) being pregnant or breastfeeding before
165 vaccination. The detailed inclusion and exclusion criteria are available at protocol 2 p
166 5.

167 Written informed consent was obtained from all participants before the enrolment
168 in the initial study. The clinical trial protocol for the study was approved by the Ethics
169 Committee of Shanxi Provincial Center for Disease Control. The study was done in
170 accordance with the Declaration of Helsinki and Good Clinical Practice. The trial was
171 registered with ChiCTR.org.cn (ChiCTR2100041705, ChiCTR2100041706).

172 **Procedures**

173 In initial study, eligible participants were recruited and randomly allocated (1: 1: 1) to
174 receive BBIBP-CorV vaccine of 4 μ g with three two-dose schedules on days 0 and 14,
175 0 and 21, or 0 and 28, respectively.

176 The responders at day 28 after priming two-dose vaccine were followed up at

177 months 3, 6 and 10 in this secondary study to evaluate the immune persistence of the
178 second dose. At month 10 after the second dose, eligible participants of three
179 two-dose schedules were received the homologous booster dose respectively
180 (hereafter abbreviated as 0-14d-10m group, 0-21d-10m group and 0-28d-10m group),
181 and followed up at day 28 post-booster to assess the safety and immunogenicity of the
182 booster dose. The vaccines were administered intramuscularly in the deltoid region of
183 the upper arm with a dosage of 4 μ g. The vaccines used in this study were inactivated
184 vaccine (Vero Cell) developed by the Beijing Institute of Biological Products (Beijing,
185 China). The contents of follow-up included the blood samples, oropharyngeal/nasal
186 swabs, and adverse reactions collection. Fig. 1 shows the study protocol.

187 **Safety assessment**

188 Safety information after the booster dose was obtained by the same methods as for
189 priming two doses [3]. Participants were observed for 30 minutes in the observation
190 room after booster dose vaccination for any acute reactions. Participants were
191 instructed to record local and systemic reactions daily for 7 days on diary cards.
192 Solicited local adverse events included pain at the injection site, induration and
193 swelling, and systemic adverse events included diarrhea and dysphagia. For days 8-28,
194 participants spontaneously reported any unsolicited adverse events including local
195 reactions (rash) and Systemic reactions (cough and headache). Adverse reactions were
196 graded according to the Guidelines for Adverse Event Classification Standards for
197 Clinical Trials of Preventive Vaccines by the National Medical Products
198 Administration (version 2019) [24].

199 **Laboratory methods**

200 Oropharyngeal/nasal swabs for RT-PCR (reverse transcriptase-polymerase chain
201 reaction) testing were collected from all participants at each follow-up point. The
202 neutralizing antibody to live SARS-CoV-2 (strain 19nCoV-CDC-Tan-Strain 05
203 [QD01]) were quantified using a micro cytopathogenic effect assay at 3, 6 and 10
204 months after the second dose, and at day 28 after the booster dose. Blood samples
205 taken at baseline and at day 28 after the second dose had been tested previously [3].
206 The lower limit of detection was 4 for the neutralizing antibody test. We defined
207 positive antibody response as a titer of 16 or greater for neutralizing antibody levels to
208 infectious SARS-CoV-2. We assessed the positive rates of neutralizing antibodies
209 with different criteria (GMT \geq 16, 32, 64, 128 or 256).

210 **Outcomes**

211 The primary immunological endpoints of the initial trials can be found in an initial
212 publication [3]. Here, we report the results of secondary and exploratory
213 immunological endpoints. Secondary immunogenic endpoints included GMT of
214 neutralizing antibody to live SARS-CoV-2, the positive rates of different criteria and

215 the constituent ratio of GMT of neutralizing antibodies (GMT 16-31, GMT 32-63,
216 GMT 64-127, GMT 128-255 and GMT \geq 256) on 3, 6 and 10 months after two dose
217 and at day 28 after booster dose. Exploratory immunogenic endpoints included the
218 kinetics of antibody levels of different vaccination regimens, predictors of
219 maintaining protected antibody levels within 10 months after two doses of vaccination
220 and the predictive duration of booster-induced neutralizing antibody declining to the
221 cutoff level of positive antibody response. The primary safety endpoints included
222 adverse events within 7 days after booster dose. Secondary safety endpoints were any
223 adverse events within 28 days after the booster dose vaccinations across the three
224 groups.

225 **Statistical analyses**

226 We followed up participants who were antibody positive at day 28 after priming
227 two-dose vaccine. During the follow-up, if the neutralizing antibody response of
228 participants was negative, they will no longer be followed up, and the antibody
229 response at each time point thereafter was negative by default. When the
230 previous observed titer was positive and still positive in the next follow-up, we
231 imputed the intermediate missing value as a positive response and the antibody titers
232 were filled according to the next follow-up. If neutralizing antibody was positive at
233 the previous follow-up and negative at the next follow-up, the intermediate missing
234 value would not be filled. The imputed nonresponses and responses and the observed
235 neutralizing antibody levels were together referred to as complete case data (see
236 appendix p 2-3).

237 The complete case data was used to calculate the GMT, positive rates and the
238 constituent ratio of neutralizing antibodies at each follow-up point. Safety endpoints
239 were presented descriptively as frequencies (%) per group. Analysis of Variance
240 (ANOVA) was used to analyze neutralizing antibody levels of different groups which
241 were log-transformed. Chi-square test or Fisher precision test was used to Categorical
242 data. The kinetics of neutralizing antibody levels, involving group, time, and
243 interaction between group and time, were analyzed by generalized estimating
244 equations (GEE), and the paired *t*-test was used to analyze the differences in
245 neutralizing antibody levels among different follow-up point [*P* value for statistical
246 significance was 0.008 (0.05/6)]. Cox proportional hazards regression model was used
247 to assess the influencing factors associated with maintaining of neutralizing antibody
248 levels during 10 months after the second dose. The nomogram was constructed to
249 predict the long-term immune persistence mainly based on the results of the Cox
250 proportional hazards regression model. The discrimination ability was assessed using
251 the Concordance indexes (C-index). C-index vary from 0.5 to 1.0 and C-index values
252 greater than 0.7 suggest a reasonable estimation.

253 An exponent curve model was used to predict the neutralizing antibody levels after
254 the booster dose, and the general form of exponential curve equation is $\hat{Y} = k + \alpha \exp$
255 (bX) . The position, direction and curvature of a curve are determined by the sign and
256 magnitude of constant terms and parameters α and b , respectively. The actual
257 antibody levels (Y) over time (X) of follow-up from 28 days (calculated according to
258 1 month) to 10 months after two doses were used to construct the model. After the
259 actual values were transformed into logarithm, reciprocal or square root, the curve
260 equation was linearized, and the least square method was used to fit the optimal
261 exponential model of vaccine immune persistence (see appendix p 13-15). Based on
262 the model, the antibody attenuation after enhancement was predicted according to the
263 actually observed neutralizing antibody titer decay after two doses. Other values of
264 $P < 0.05$ were considered statistically significant. The nomogram was performed using
265 R software, version 4.1.3. Other statistical computations were performed using SAS
266 version 9.4 and graphing performed using GraphPad Prism 9.0.0.

267 **Result**

268 **Participants' characteristics at baseline**

269 A total of 809 participants were enrolled and randomly assigned to the 0-14d (n=270),
270 0-21d (n=270) and 0-28d (n=269) schedule, respectively. The responders (256, 247
271 and 241 participants) at day 28 after priming two-dose vaccination were followed-up
272 at months 3, 6, and 10 for immune persistence evaluation, respectively. At month 10
273 after second dose, a total of 390 participants were eligible and received a booster dose,
274 with 130 participants in the 0-14d-10m, 0-21d-10m and 0-28d-10m group respectively,
275 of whom 74.1% (289/390) were male and 25.9% (101/390) were female, with a mean
276 age of 37.1 ± 10.3 years. There were 122, 120 and 112 participants in three groups
277 completed blood sampling at 28 days after the booster dose (Fig. 2; Table 1). The
278 demographic characteristics were broadly similar between the participants who
279 received booster dose of vaccine and no vaccination. There was no difference in
280 demographics characteristics among the three groups at each follow-up point (see
281 appendix p 4-8).

282 **GMT , positive rates and constituent ratio of SARS-CoV-2 neutralizing** 283 **antibodies at each follow-up point in three groups**

284 The GMT of neutralizing antibodies at month 3 after the second dose was 46.4
285 [95% confidence interval (CI): 41.4~52.0] in the 0-14d-10m group, which was
286 significantly lower than 64.2 (95%CI: 58.8~70.1) in the 0-21d-10m group ($P < 0.0001$),
287 and 71.6 (95%CI: 65.7~78.0) in the 0-28d-10m group ($P < 0.0001$). The GMT of
288 neutralizing antibodies at month 6 after the second dose reduced to 30.5 (95%CI:
289 27.0~34.5) in the 0-14d-10m group, 42.8 (95%CI: 39.2~46.7) in the 0-21d-10m group
290 ($P < 0.0001$ vs 0-14d-10m group), and 47.1 (95%CI: 42.2~52.6) in the 0-28d-10m

291 group ($P<0.0001$ vs 0-14d-10m group). At month 10 after the second dose, the GMT
292 of neutralizing antibodies declined to 20.3 (95%CI: 17.4~23.6) in the 0-14d-10m
293 group, 28.8 (95%CI: 25.5~32.6) in 0-21d-10m group ($P=0.0004$, vs 0-14d-10m
294 group), and 32.4 (95%CI: 28.7~36.6) in the 0-28d-10m group ($P<0.0001$, vs
295 0-14d-10m group). (Fig. 3; see appendix p 9). Results of post-booster immunogenicity
296 analysis showed that the GMT on day 28 after booster vaccination increased to 246.2
297 (95%CI: 222.6-269.7), 277.5 (95%CI: 248.9-306.0) and 288.6 (95%CI: 256.9-320.3)
298 in 0-14d-10m, 0-21d-10m and 0-28d-10m group, respectively (Fig. 3). There was no
299 significant difference in the GMT of post-booster neutralizing antibodies among the
300 three groups ($P>0.05$) (see appendix p 9).

301 From month 3 to 10 after the second dose, the positive rates of neutralizing
302 antibodies decreased from 96.3% (237/246) to 76.7% (132/172) in the 0-14d-10m
303 group, from 99.2% (233/235) to 86.5% (147/170) in the 0-21d-10m group and from
304 98.7% (228/231) to 89.8% (141/157) in the 0-28d-10m group, respectively. At 28
305 days after booster dose, positive rates in all vaccination groups markedly increased in
306 100.0%. (Fig. 5; see appendix p 9). Details of the positive rates of neutralizing
307 antibodies with different criteria at each follow-up point can be found in the appendix
308 p 9.

309 On day 28 after the second dose, the constituent ratio of neutralizing antibodies was
310 higher at the GMT 64-127 (29.3%, 75/256) in the 0-14d-10m group, while the
311 constituent ratio of neutralizing antibodies in the 0-21d-10m and 0-28d-10m group
312 was higher at the GMT of 64-127 (28.8%, 71/247; 29.5%, 71/241) and 128-255
313 (40.9%, 101/247; 34.0%, 82/241), respectively. However, on 10 months after the
314 second dose, the constituent ratio of neutralizing antibodies was sharply decrease at
315 the GMT 64-127 (9.9%, 13/132) in the 0-14d-10m group, while the constituent ratio
316 of neutralizing antibodies in the 0-21d-10m and 0-28d-10m groups was remarkably
317 decrease at the GMT of 64-127 (15.7%, 23/147; 23.4%, 33/141) and 128-255 (0.0%,
318 0/147; 1.4%, 2/141), respectively. On day 28 after booster vaccination, a strangely
319 rebound in the constituent ratio of neutralizing antibodies was observed at the GMT
320 128-255 (35.2%, 43/122; 34.2%, 41/120; 34.8%, 39/112) and $\text{GMT}\geq 256$ (48.4%,
321 59/122; 56.7%, 68/120; 56.3%, 63/112) in three groups, respectively (Fig. 4, see
322 appendix p 10).

323 **Kinetics of SARS-CoV-2 neutralizing antibodies in three groups and predictive** 324 **antibody decay after booster dose**

325 From day 28 to month 10 after second dose, a substantial reduction of
326 SARS-CoV-2 neutralizing antibodies by 4.85-fold (GMT: from 98.4 to 20.3,
327 $P<0.0001$), 4.67-fold (GMT: from 134.4 to 28.8, $P<0.0001$) and 4.49-fold (GMT:
328 from 145.5 to 32.4, $P<0.0001$) were observed in 0-14d-10m group, 0-21d-10m group
329 and 0-28d-10m group, respectively. In the whole process, the GMT of neutralizing

330 antibodies decreased more rapidly of 2.12-fold (GMT: from 98.4 to 46.4, $P<0.0001$),
331 2.09-fold (GMT: from 134.4 to 64.2, $P<0.0001$) and 2.03-fold (GMT: from 145.5 to
332 71.6, $P<0.0001$) from days 28 to months 3, but slowed thereafter in three groups,
333 respectively (Table 3). The kinetic profile was similar among three groups by GEE
334 ($P=0.67$) (Fig. 6; Table 2). On day 28 post-booster-vaccination, the GMT of
335 neutralizing antibodies increased from pre-boosting levels (10 months after the second
336 dose) by 12.16-fold (GMT: from 20.3 to 246.2, $P<0.0001$) in 0-14d-10m group, by
337 9.64-fold (GMT: from 28.8 to 277.5, $P<0.0001$) in the 0-21d-10m group and by
338 8.91-fold (GMT: from 32.4 to 288.6, $P<0.0001$) in the 0-28d-10m group, respectively.
339 Correspondingly, booster vaccination led to 2.50-fold (GMT: from 98.4 to 246.2,
340 $P<0.0001$), 2.06-fold (GMT: from 134.4 to 277.5, $P<0.0001$) and 1.98-fold (GMT:
341 from 145.5 to 288.6, $P<0.0001$) increases from day 28 after the second dose to day 28
342 post-booster in the GMT of neutralizing antibodies in three groups, respectively
343 (Table 3).

344 The GMT of neutralizing antibodies from day 28 to month 10 of the second dose in
345 0-14d-10m group, 0-21d-10m group and 0-28d-10m group were used to construct
346 decreased exponent curve model, respectively. The exponential curve equation was
347 $\hat{Y}=91.38 \exp(-0.16X)$, $\hat{Y}=127.10 \exp(-0.16X)$ and $\hat{Y}=138.38 \exp(-0.16X)$ in three
348 groups, respectively. The coefficient of determination R Squared was 0.85, 0.86 and
349 0.86 respectively. The antibody attenuation after booster dose was predicted according
350 to the exponential curve model of antibody decay after two doses. The results of the
351 three groups on the day 28 after booster dose were respectively substituted into the
352 exponent model, time 28d (calculated according to 1 month) = 1, and the calculated
353 parameter α values were 288.92, 325.65 and 338.67 respectively. So, the exponential
354 curve equation for the 0-14d-10m group was $\hat{Y}=288.92 \exp(-0.16X)$, for the
355 0-21d-10m group was $\hat{Y}=325.65 \exp(-0.16X)$, and for the 0-28d-10m group was
356 $\hat{Y}=338.67 \exp(-0.16X)$. It can be seen that the GMT of neutralizing antibodies may
357 decrease by approximately 55% on 6 months post-booster and the predictive duration
358 of booster-induced neutralizing antibody declining to the cutoff level of positive
359 antibody response (GMT of 16) may be 18.08 months, 18.83 months and 19.08
360 months in three groups, respectively (Fig. 6; see appendix p 13-15).

361 **Predictors of SARS-CoV-2 neutralizing antibody durability within 10 months** 362 **after the second dose**

363 The results of Cox proportional hazards regression showed that the participants
364 with age ≥ 40 ($HR=1.883$, $95\%CI$: 1.064~3.333, $P=0.03$) were associated with a high
365 risk of response loss (GMT<16). The participants who were in 0-28d-10m group
366 ($HR=0.353$, $95\%CI$: 0.182~0.683, $P=0.0020$), had an influenza vaccination history
367 ($HR=0.554$, $95\%CI$: 0.336~0.912, $P=0.02$) or were female ($HR=0.299$, $95\%CI$:
368 0.151~0.593, $P=0.0005$) tended to maintain immune persistence during 10 months

369 after the second dose (Fig. 7). The four factors above were used to construct a
370 nomogram to predict neutralizing antibody decline probability during 10 months. The
371 nomogram showed that the largest contributions of maintaining immune persistence
372 were age and sex, followed by group and influenza vaccination history (Fig. 8). The
373 C-index for the prediction nomogram was 0.70 for the training cohort (see appendix p
374 11).

375 **Safety**

376 A total of 390 participants who complete the booster dose were included in safety
377 analysis, the overall incidence of adverse reactions was 1.5% (2/130), 4.6% (6/130),
378 and 3.1% (4/130) in the 0-14d-10m, 0-21d-10m and 0-28d-10m group after the
379 booster dose, with no significant difference among the three groups ($P=0.41$). The
380 most common reported reaction was injection-site pain, which occurred in 2 of 130
381 (1.5%), 3 of 130 (2.3%), and 1 of 130 (0.8%) participants in the three groups ($P=0.87$).
382 Solicited adverse reactions were reported by 2 (1.5%) participants in the 0-14d-10m
383 group, 4 (3.1%) participants in the 0-21d-10m group, and 3 (2.3%) participants in the
384 0-28d-10m group within 7 days after injection. All adverse reactions were mild after
385 the booster injection. The vaccine showed a favorable safety profile from month 3 to
386 10 after second dose. None of the participants were infected SARS-CoV-2 during the
387 trial period (Fig. 9; see appendix p 12).

388 **Discussion**

389 Recent studies reported the long-term immune persistence after the priming
390 full-schedule vaccination and the safety and immunogenicity of booster dose with
391 different technical platform COVID19 vaccines in different population [11-17, 21-23].
392 However, a complete picture of the kinetics of immune response among persons with
393 different vaccination regimens of BBIBP-CorV is not yet available, and the safety and
394 immunogenicity of homologous booster vaccination are yet to be thoroughly
395 evaluated, especially in the high-risk occupational population. Based on our previous
396 research, we assessed immune persistence of a priming two-dose BBIBP-CorV
397 vaccine schedule, and found that the long-term persistent immunogenicity in
398 0-21d-10m and 0-28d-10m group was more satisfactory than that in 0-14d-10m group
399 in public security officers and airport ground staff. Besides, maintaining long-term
400 immune persistence was also associated with age<40, female, and history of influenza
401 vaccination. A booster dose given at month 10 after the second dose led to a strong
402 increase in neutralizing antibody which was not affected by the priming two-dose
403 vaccination regimen, and the predictive duration of neutralizing antibody declining to
404 the cutoff level of positive antibody response may be above 18 months in three
405 groups.

406 To our knowledge, this research firstly reported the finding that a priming two-dose
407 schedule of day 0-28 and day 0-21 could lead to longer persistence of neutralizing

408 antibody compared to day 0-14 in the high-risk occupational population. Our initial
409 study demonstrated that a priming vaccination regimen of day 0-21 and day 0-28
410 induced higher peak value of neutralizing antibodies at day 28 after the second dose
411 [3]. Previous studies [25] demonstrated that the persistence of immune response was
412 correlated with the peak antibody levels. That may account for the higher neutralizing
413 antibody levels at each follow-up point from month 3 to month 10 after the second
414 dose in 0-21d-10m and 0-28d-10m group.

415 Our results suggested that from day 28 to month 10 after the second dose, a
416 decrease by 4.85-fold (GMT: 94.4-20.3), 4.67-fold (GMT: 134.4-28.8) and 4.49-fold
417 (GMT: 145.5-32.4) was observed in the 0-14d-10m, 0-21d-10m and 0-28d-10m group,
418 respectively. Other studies also evaluated the persistence of neutralizing antibodies
419 induced by different inactivated vaccines. Zeng et al [13] found that neutralizing
420 antibody titers induced by two doses (two schedules of day 0-14, day 0-28)
421 CoronaVac vaccines (3 μ g) both declined after 6 months to below the seropositive
422 cutoff (GMT of 8). Another study [14] reported that the neutralizing antibodies
423 induced by the two doses of BBIBP-CorV (3 μ g, 28 days apart) decreased by a factor
424 of 2.94 (GMT: from 6.8 to 2.3) from month 2 to month 6. Similarly, one
425 non-peer-reviewed study [16] in Indian found that the GMT of neutralizing antibodies
426 decreased 8.24-fold from 28 days after a second BBV152 vaccination to 6 months
427 later. In addition, neutralizing antibodies decreased over time after initial vaccination
428 has been observed with mRNA vaccines and adenovirus-vectored vaccines et al, but
429 to a lesser extent than those of inactivated vaccines [12, 15]. Overall, neutralizing
430 antibody responses elicited by all kinds of COVID-19 vaccines after priming
431 full-schedule vaccination, subsequently declining to varying degrees over time, which
432 may be due to differences in vaccine technology platforms, study population or test
433 methods et al.

434 Published data revealed that innate and adaptive immunity was decreased with age,
435 particularly in vaccine responses [26]. Wang and colleagues [17] found that geometric
436 mean concentrations of both inactivated vaccines (BBIBP-CorV and CoronaVac)
437 decreased with age, especially in the 50-59 age group. A prospective longitudinal
438 cohort study [18] also found that humoral response was substantially decreased 6
439 months after receipt of the second dose of the BNT162b2 vaccine, especially among
440 persons 65 years of age or older. Consistent with previous studies, our results also
441 found that the participants with age \geq 40 were associated with a high risk of response
442 loss. Meanwhile, we found that persistence of neutralizing antibodies was better in
443 women than in men, which was similar to the findings in other reports [17, 18]. It
444 probably caused by immune function differences between the sexes. Mechanisms
445 implicated in mediating sex-based differences in immune responses may include

446 immunological, sex steroid hormones, genetic and epigenetic regulation, and
447 microbiota differences et al [27].

448 We also found that history of influenza vaccination had a positive impact on the
449 immune persistence of the SARS-CoV-2 vaccine [The median time from the influenza
450 vaccination to the first dose of BBIBP-CorV vaccine was 80.74 days, interquartile
451 range (IQR) 71.70-90.74]. A real-world study [28] revealed that
452 influenza/pneumococcal vaccination seems to have a substantial impact on the
453 neutralization response to BNT162b2 mRNA vaccination (The median time from the
454 influenza and pneumococcal vaccination to the second dose of SARS-CoV-2 vaccine
455 was 102 days). It is speculated that influenza vaccine may affect the persistence of the
456 COVID-19 vaccine by affecting its immunogenicity. It may be related to the
457 non-specific effects of vaccines [29].

458 Several studies reported that the homologous booster dose with inactivated
459 vaccines led to a strangely rebound in neutralizing immune response against
460 SARS-CoV-2. A non-peer-reviewed study [21] found the GMT of neutralizing
461 antibodies was improved 1.04-3.87-fold on day 30 after a booster dose of
462 BBIBP-CorV vaccine compared to the 28 days after the second dose. Similarly, one
463 study [14] of 353 healthy adult participants who administered with a two-shot
464 regiment (28 days apart) BBIBP-CorV vaccine (month 1) and a booster dose 7
465 months later, the GMT increased 4.5 times, compared to GMT of month 2. Another
466 non-peer-reviewed study [30] reported that a booster vaccination at 8 to 9 months
467 after priming two-dose BBIBP-CorV vaccine led to a 6.1-fold increase in the
468 neutralization GMT against the wild-type strain. Besides, some studies also revealed
469 that a heterologous boost following prime vaccination could also elicit remarkably
470 protection against SARS-CoV-2 [21, 23]. Consistent with previous studies, our
471 research indicated that on 28 days after the homologous booster dose, GMT of
472 neutralizing antibodies were increased by 8.91-12.16-fold compared to the
473 pre-boosting levels and 1.98-2.50 fold compared to the 28 days after the second dose
474 levels. Overall, the booster dose could significantly reverse the decrease in
475 neutralizing antibodies after the second dose, which may be explained by that the
476 priming two-dose vaccination could induce efficient T and B memory cells and
477 booster vaccination could significantly recall and enhance antibody responses [8, 9,
478 16].

479 Notably, our results indicated that a booster dose given at month 10 after the second
480 dose produced similar immunogenicity (246.2, 277.5 and 288.6) among the three
481 groups, which was not affected by the priming two-dose vaccination regimen. It
482 means that booster dose could reverse the lower GMT of neutralizing antibodies of 14
483 days intervals at some extent. Meanwhile the results also highlighted the essential for

484 booster vaccination to top-up the immune response. Of course, these results should be
485 confirmed by large-scale clinical studies.

486 Furthermore, using the exponent curve model, we predicted that the GMT of
487 neutralizing antibodies may decrease by approximately 55% at 6 months post-booster
488 and the predictive duration of neutralizing antibodies declining to the cutoff level of
489 positive antibody response may be above 18 months in three groups. One
490 non-peer-reviewed study [31] in China reported that the GMT of neutralization
491 antibody against an ancestral SARS-CoV-2 viral strain (Wuhan-Hu-1) drastically
492 decreased by approximately 85% at 6 months after the booster dose of inactivated
493 vaccines. Our model prediction results showed a satisfactory long-term durability of
494 neutralizing antibodies in high-risk occupational population, and data will be collected
495 as verified the prediction results in the future.

496 This study has some limitations. Firstly, neutralization tests in vitro against emerging
497 Omicron variant were not assessed in our study. Several studies have shown
498 vaccine-induced immune protection might more likely be escaped by Omicron
499 compared to prototypes and other VOCs, while a booster dose improved
500 neutralization against Omicron [30, 32, 33], and we will further explore. Secondly, we
501 only reported persistence of a two-dose schedule data and immunogenicity and safety
502 of a booster dose data for the high-risk occupational population aged 18 to 59 years.
503 Although the population aged 60 years and older was not evaluated in this study, our
504 study still suggested that older people (age \geq 40) have faster neutralizing antibody
505 decay. Thirdly, the C-index of our nomogram was not satisfactory enough, however, it
506 could reflect the predictors of antibody decay in some extent. Finally, a relatively high
507 rate of loss to follow-up is unavoidable during the follow-up. However, there were no
508 differences in the rates of loss to follow-up among the three groups.

509 **Conclusions**

510 In conclusion, the priming two-dose BBIBP-CorV vaccine with 0-28 days and 0-21
511 days schedule could lead a longer persistence of neutralizing antibody than 0-14 days
512 schedule. Maintaining long-term immune persistence was also associated with age $<$ 40,
513 female, and history of influenza vaccination. Regardless of priming two-doses
514 vaccination regimens, a homologous booster dose led to a strong rebound in
515 neutralizing antibody and might elicit satisfactory persistent immunity.

516 **Abbreviations**

517 SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; COVID-19:
518 Coronavirus disease 2019; GMT: Geometric mean titer; CI: Confidence interval; BMI:
519 Body mass index; RT-PCR: Reverse transcriptase-polymerase chain reaction; WHO:
520 World Health Organization.

521 **Acknowledgments**

522 This research was supported by the COVID-19 Project of Shanxi Provincial Finance,
523 and the Project of Shanxi Provincial Key Laboratory for major infectious disease
524 response. Thanks for gratefully all participants taking part in this research. We
525 gratefully acknowledge the contribution from our colleagues and students, and staff
526 members of the Shanxi Provincial Center for Disease Control and Outpatient
527 Department of Shanxi Aviation Industry Group Co.LTD.

528 **Authors' Contributors**

529 Tian Yao: conceptualization, conceived and developed the overall study design,
530 reviewed and interpreted data, investigated and performed experiments, and drafted
531 the manuscript. Xiaohong Zhang, Shengcai Mu: conceptualization, conceived and
532 designed the study, analyzed the data, reviewed and interpreted data, investigated and
533 performed experiments. Yana Guo, Xiuyang Xu: analyzed the data, reviewed and
534 interpreted data, investigated and performed experiments. Junfeng Huo, Zhiyun Wei,
535 Ling Liu, Xiaoqing Li, Hong Li, Rongqin Xing: investigated and performed
536 experiments. Yongliang Feng & Jing Chen & Lizhong Feng & Suping Wang:
537 conceptualization, conceived and designed the study, reviewed and interpreted data,
538 writing-review & editing.

539 **Funding**

540 The study was supported by the COVID-19 Project of Shanxi Provincial Finance, the
541 Project of Shanxi Provincial Key Laboratory for major infectious disease response,
542 and the COVID-19 Scientific Research Project of Health Commission of Shanxi
543 Provincial.

544 **Availability of data and materials**

545 In this study, the full protocol and the datasets are available, following manuscript
546 publication, upon request from the corresponding author (Professor Suping Wang,
547 supingwang@sxmu.edu.cn), following the provision of ethics approval.

548 **Declarations**

549 **Ethics approval and consent to participate**

550 The study was approved by the Ethics Committee of Shanxi Provincial Center for
551 Disease Control (SXCDCIRBPJ2020056001) and Prevention and the Chinese Clinical
552 Trial Registry (ChiCTR2100041705, ChiCTR2100041706).

553 **Consent for publication**

554 Not applicable.

555 **Competing interests**

556 All authors declare that they have no competing interests.

557

558 **Reference**

559

560 1. WHO Coronavirus (COVID-19) Dashboard. <https://covid19.who.int/> (accessed Jun 21,

- 561 2022).
- 562 2. **WHO lists additional COVID-19 vaccine for emergency use and issues interim policy**
- 563 **recommendations.**
- 564 <https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emerge>
- 565 [ncy-use-and-issues-interim-policy-recommendations](https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emerge) (accessed Jun 1, 2022).
- 566 3. Feng Y, Chen J, Yao T, Chang Y, Li X, Xing R, Li H, Xie R, Zhang X, Wei Z *et al*: **Safety and**
- 567 **immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational**
- 568 **population: a randomized, parallel, controlled clinical trial.** *Infect Dis Poverty* 2021,
- 569 **10(1):138.**
- 570 4. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z *et al*: **Safety**
- 571 **and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a**
- 572 **randomised, double-blind, placebo-controlled, phase 1/2 trial.** *Lancet Infect Dis* 2021,
- 573 **21(1):39-51.**
- 574 5. Krammer F: **A correlate of protection for SARS-CoV-2 vaccines is urgently needed.**
- 575 *Nat Med* 2021, **27(7):1147-48.**
- 576 6. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ,
- 577 Triccas JA, Davenport MP: **Neutralizing antibody levels are highly predictive of**
- 578 **immune protection from symptomatic SARS-CoV-2 infection.** *Nat Med* 2021,
- 579 **27(7):1205-11.**
- 580 7. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, Dull P,
- 581 Plotkin SA: **Evidence for antibody as a protective correlate for COVID-19 vaccines.**
- 582 *Vaccine* 2021, **39(32):4423-28.**
- 583 8. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, Lundgreen KA,
- 584 Reynaldi A, Khoury DS, Pattekar A *et al*: **mRNA vaccines induce durable immune**
- 585 **memory to SARS-CoV-2 and variants of concern.** *Science* 2021, **374(6572):abm0829.**
- 586 9. Liu Y, Zeng Q, Deng C, Li M, Li L, Liu D, Liu M, Ruan X, Mei J, Mo R *et al*: **Robust**
- 587 **induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2**
- 588 **vaccine.** *Cell Discov* 2022, **8(1):10.**
- 589 10. VanBlargan LA, Goo L, Pierson TC: **Deconstructing the Antiviral**
- 590 **Neutralizing-Antibody Response: Implications for Vaccine Development and**
- 591 **Immunity.** *Microbiol Mol Biol Rev* 2016, **80(4):989-1010.**
- 592 11. Pegu A, O'Connell SE, Schmidt SD, O'Dell S, Talana CA, Lai L, Albert J, Anderson E,
- 593 Bennett H, Corbett KS *et al*: **Durability of mRNA-1273 vaccine-induced antibodies**
- 594 **against SARS-CoV-2 variants.** *Science (New York, NY)* 2021, **373(6561):1372-77.**
- 595 12. Barouch DH, Stephenson KE, Sadoff J, Yu J, Chang A, Gebre M, McMahan K, Liu J,
- 596 Chandrashekar A, Patel S *et al*: **Durable Humoral and Cellular Immune Responses 8**
- 597 **Months after Ad26.COVS.2 Vaccination.** *N Engl J Med* 2021, **385(10):951-3.**
- 598 13. Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, Wu Z, Jiang D, Deng X, Chu K *et al*:
- 599 **Immunogenicity and safety of a third dose of CoronaVac, and immune persistence**
- 600 **of a two-dose schedule, in healthy adults: interim results from two single-centre,**
- 601 **double-blind, randomised, placebo-controlled phase 2 clinical trials.** *Lancet Infect*
- 602 *Dis* 2022, **22(4):483-95.**
- 603 14. Cheng ZJ, Huang H, Zheng P, Xue M, Ma J, Zhan Z, Gan H, Zeng Y, Lin R, Li S *et al*:
- 604 **Humoral immune response of BBIBP COVID-19 vaccination before and after the**

- 605 **booster immunization.** *Allergy* 2022.
- 606 15. Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B,
607 Ledgerwood JE, Mascola JR, Graham BS, Lin BC *et al.* **Antibody Persistence through 6**
608 **Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.** *N Engl J Med*
609 2021, **384**(23):2259-61.
- 610 16. Vadrevu KM, Ganneru B, Reddy S, Jogdand H, Raju D, Praturi U, Sapkal G, Yadav P, Reddy
611 P, Verma S *et al.* **Persistence of immunity and impact of a third (booster) dose of an**
612 **inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised**
613 **controlled trial.** *medRxiv.* 2022; <https://doi.org/10.1101/2022.01.05.22268777>.
- 614 17. Wang f, Huang B-Y, Lv H, Feng L, Ren W, Wang X, Tang L, Liu Q, Wu D, Zheng H *et al.*
615 **Kinetics and Factors Associated With 12-Month Persistence of Neutralizing**
616 **Antibody Induced by Two Inactivated COVID-19 Vaccines.** *SSRN* 2022;
617 <https://ssrn.com/abstract=4065610>.
- 618 18. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, Doolman R, Asraf K,
619 Mendelson E, Ziv A *et al.* **Waning Immune Humoral Response to BNT162b2 Covid-19**
620 **Vaccine over 6 Months.** *The New England journal of medicine* 2021, **385**(24):e84-e84.
- 621 19. Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, Indenbaum V, Mandelboim
622 M, Doolman R, Amit S *et al.* **BNT162b2 COVID-19 vaccine and correlates of humoral**
623 **immune responses and dynamics: a prospective, single-centre, longitudinal cohort**
624 **study in health-care workers.** *Lancet Respir Med* 2021, **9**(9):999-1009.
- 625 20. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie
626 VL, Barnabas SL, Bhorat QE *et al.* **Single-dose administration and the influence of the**
627 **timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19**
628 **(AZD1222) vaccine: a pooled analysis of four randomised trials.** *Lancet* 2021,
629 **397**(10277):881-891.
- 630 21. Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, Kang Y, Su JG, Zhang J, Yang T *et al.*
631 **Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV**
632 **recipients: a randomized controlled phase 2 trial.** *medRxiv.* 2022;
633 <https://doi.org/10.1101/2022.03.08.22272062>.
- 634 22. Falsey AR, Frenck RW, Jr., Walsh EE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Bailey R,
635 Swanson KA, Xu X *et al.* **SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.**
636 *N Engl J Med* 2021, **385**(17):1627-29.
- 637 23. Ai J, Zhang H, Zhang Q, Zhang Y, Lin K, Fu Z, Song J, Zhao Y, Fan M, Wang H *et al.*
638 **Recombinant protein subunit vaccine booster following two-dose inactivated**
639 **vaccines dramatically enhanced anti-RBD responses and neutralizing titers against**
640 **SARS-CoV-2 and Variants of Concern.** *Cell research* 2022, **32**(1):103-6.
- 641 24. **The Guidelines for Adverse Event Classification Standards for Clinical Trials of**
642 **Preventive Vaccines.** 2019.
643 <https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20191231111901460.html> (accessed Jun 1,
644 2022).
- 645 25. Yao T, Shao Z, Wu L, Dong S, Gao L, Wu Y, Shi X, Shi J, Liu G, Wang J *et al.* **Long-term**
646 **persistent immunogenicity after successful standard and triple-dosed hepatitis B**
647 **vaccine in hemodialysis patients: A 3-year follow-up study in China.** *Vaccine* 2021,
648 **39**(18):2537-44.

- 649 26. Poland GA, Ovsyannikova IG, Kennedy RB: **Personalized vaccinology: A review.** *Vaccine*
650 2018, **36**(36):5350-57.
- 651 27. Klein SL, Marriott I, Fish EN: **Sex-based differences in immune function and responses**
652 **to vaccination.** *Trans R Soc Trop Med Hyg* 2015, **109**(1):9-15.
- 653 28. Puro V, Castilletti C, Agrati C, Goletti D, Leone S, Agresta A, Cimini E, Tartaglia E, Casetti R,
654 Colavita F *et al.* **Impact of Prior Influenza and Pneumococcal Vaccines on Humoral**
655 **and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination.** *Vaccines (Basel)* 2021,
656 **9**(6):615.
- 657 29. Messina NL, Zimmermann P, Curtis N: **The impact of vaccines on heterologous**
658 **adaptive immunity.** *Clin Microbiol Infect* 2019, **25**(12):1484-93.
- 659 30. Yu X, Wei D, Xu W, Li Y, Li X, Zhang X, Qu J, Yang Z, Chen E: **Pseudotyped SARS-CoV-2**
660 **Omicron variant exhibits significant escape from neutralization induced by a third**
661 **booster dose of vaccination.** *medRxiv.* 2021;
662 <https://doi.org/10.1101/2021.12.17.21267961>.
- 663 31. Wang J, Deng C, Liu M, Liu Y, Li L, Huang Z, Shang L, Jiang J, Li Y, Mo R *et al.* **Four doses**
664 **of the inactivated SARS-CoV-2 vaccine redistribute humoral immune responses**
665 **away from the Receptor Binding Domain.** *medRxiv.* 2022;
666 <https://doi.org/10.1101/2022.02.19.22271215>.
- 667 32. Wang X, Zhao X, Song J, Wu J, Zhu Y, Li M, Cui Y, Chen Y, Yang L, Liu J *et al.*
668 **Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2**
669 **Omicron variant escape from neutralizing antibodies.** *Emerg Microbes Infect* 2022,
670 **11**(1):477-481.
- 671 33. Ai J, Zhang H, Zhang Y, Lin K, Zhang Y, Wu J, Wan Y, Huang Y, Song J, Fu Z *et al.*
672 **Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2**
673 **variants to immune sera elicited by vaccines after boost.** *Emerg Microbes Infect* 2022,
674 **11**(1):337-343.
- 675




Figure 1: Trial process timeline




Figure 2: Flow of participants in a study of the inactivated SARS-CoV-2 vaccine in high-risk occupational population

* Participants who were antibody positive (GMT≥16) could be followed up

**Lost to follow-up including transfer, business trip or physical discomfort

nAb: neutralizing antibody




Figure 3: Neutralizing antibody titers of SARS-CoV-2 vaccine at each follow-up point in high-risk occupational population

Dots are reciprocal neutralizing antibody titers for individuals in the different groups. The bars represent GMT, and the error bars indicate the 95% CI. The dotted horizontal line represents the positive response threshold. GMT=geometric mean titer.




Figure 4: Constituent ratio of neutralizing antibodies at each follow-up point in high-risk occupational population.




Figure 5: Positive rate within different criteria at each follow-up point in high-risk occupational population




Figure 6: Kinetics of the GMT of SARS-CoV-2 neutralizing antibodies

A: Day 28 after the second dose; B: Month 10 after the second dose, booster dose; C: Day 28 after the booster dose.

The curve from point A to point C is the actual observed value of follow-up, and the curve after point C is the predicted value by exponential curve model. The bottom axis is the time after booster dose vaccination. The dotted horizontal line represents the positive antibody response threshold.




Figure 7: Influence factors of antibody loss by cox proportional hazard regression analysis




Figure 8: The predictors of the long-term immune persistence based on nomogram.

The nomogram consists of graphical lines including predictors [age, sex, history of vaccination (The type of vaccine is influenza vaccine), difference groups], single score, total score, linear predictive value and event (Predicted of neutralizing antibody (nAb) remaining positive within 10 months). The scale is marked on the line segment corresponding to each predictor to represent the value range of the predictor, and the length of the line segment reflects the contribution of the predictor to the outcome event. The top single score in the picture shows the corresponding score of predictors under different values. The total score of all predictors is scored by single score. The corresponding linear prediction can be obtained. The lowest line represents the probability of SARS-CoV-2 neutralizing antibody remaining positive within 10 months.




Figure 9: Incidence of solicited and unsolicited adverse reactions occurred within 28 days after the booster dose.

Table 1: Demographic and Behavioral Characteristics of High-risk Occupational Population who received the Booster Dose

Characteristics	Total n=390	0-14d-10m group n=130	0-21d-10m group n=130	0-28d-10m group n=130	<i>P</i>
Sex					0.13
Male	289(74.1%)	95(73.1%)	90(69.2%)	104(80.0%)	
Female	101(25.9%)	35(26.9%)	40(30.8%)	26(20.0%)	
Age(years)					0.14
<40	234(60.0%)	72(55.4%)	75(57.7%)	87(66.9%)	
≥40	156(40.0%)	58(44.6%)	55(42.3%)	43(33.1%)	
Education level					0.38
Junior high school or lower	46(11.8%)	19(14.6%)	17(13.1%)	10(7.7%)	
Senior high school	26(6.7%)	8(6.2%)	7(5.4%)	11(8.5%)	
College or higher	318(81.5%)	103(79.2%)	106(81.5%)	109(84.8%)	
Marital status					0.54
Married	295(75.6%)	104(80.0%)	92(70.8%)	99(76.2%)	
Unmarried	85(21.8%)	23(17.7%)	34(26.1%)	28(21.5%)	
Divorced or widowed	10(2.6%)	3(2.3%)	4(3.1%)	3(2.3%)	
Ethnicity					1.00
Han ethnicity	382(97.9%)	128(98.5%)	127(97.7%)	127(97.7%)	
Other	8(2.1%)	2(1.5%)	3(2.3%)	3(2.3%)	
BMI(kg/m ²)					0.74
<24	179(45.9%)	62(47.7%)	61(46.9%)	56(43.1%)	
≥24	211(54.1%)	68(52.3%)	69(53.1%)	74(56.9%)	
Influenza vaccination history					0.88
No	267(68.5%)	91(70.0%)	89(68.5%)	87(66.9%)	
Yes	123(31.5%)	39(30.0%)	41(31.5%)	43(33.1%)	

Results expressed as n (%), BMI=body-mass index.

Table 2: Kinetics of SARS-CoV-2 neutralizing antibody decay from day 28 to months 10 after the second dose vaccination by generalized estimating equations

Characteristics	Estimate	Standard Error	Z	P
Intercept	1.982	0.038	52.280	<0.0001
time	-0.194	0.018	-10.830	<0.0001
group	0.089	0.018	5.040	<0.0001
time*group	0.004	0.008	0.430	0.67

Table 3: The differences of SARS-CoV-2 neutralizing antibody titers between different follow-up point by paired t-test

group	Time interval	Fold	Time interval	Fold
0-14d-10m	D ₂₈ --M ₃ [*]	2.12 ^d	M ₃ --M ₆ [*]	1.52 ^d
	D ₂₈ --M ₆ [*]	3.22 ^d	M ₃ --M ₁₀ [*]	2.29 ^d
	D ₂₈ --M ₁₀ [*]	4.85 ^d	M ₆ --M ₁₀ [*]	1.50 ^d
	D ₂₈ --D ₂₈ ^{b#}	2.50 ⁱ	M ₁₀ --D ₂₈ ^{b#}	12.16 ⁱ
0-21d-10m	D ₂₈ --M ₃ [*]	2.09 ^d	M ₃ --M ₆ [*]	1.50 ^d
	D ₂₈ --M ₆ [*]	3.14 ^d	M ₃ --M ₁₀ [*]	2.23 ^d
	D ₂₈ --M ₁₀ [*]	4.67 ^d	M ₆ --M ₁₀ [*]	1.49 ^d
	D ₂₈ --D ₂₈ ^{b#}	2.06 ⁱ	M ₁₀ --D ₂₈ ^{b#}	9.64 ⁱ
0-28d-10m	D ₂₈ --M ₃ [*]	2.03 ^d	M ₃ --M ₆ [*]	1.52 ^d
	D ₂₈ --M ₆ [*]	3.09 ^d	M ₃ --M ₁₀ [*]	2.21 ^d
	D ₂₈ --M ₁₀ [*]	4.49 ^d	M ₆ --M ₁₀ [*]	1.45 ^d
	D ₂₈ --D ₂₈ ^{b#}	1.98 ⁱ	M ₁₀ --D ₂₈ ^{b#}	8.91 ⁱ

D₂₈: Day 28 after second dose; M₃: Month 3 after second dose; M₆: Month 6 after second dose; M₁₀: Month 10 after second dose;

D₂₈^b: Day 28 after booster dose

^{*} P-value of <0.008 (0.05/6) was considered significant

[#] P-value of <0.05 was considered significant

^d Declining fold of neutralizing antibody GMT

ⁱ Increasing fold of neutralizing antibody GMT